Metastatic Germ Cell Tumours

被引：0

作者：

Massard, C. ^{[1
]}

Loriot, Y. ^{[1
]}

Fizazi, K. ^{[1
]}

机构：

[1] Dept Med Oncol, Villejuif, France

来源：

ONCOLOGIE | 2014年 / 16卷 / 04期

关键词：

Germ cell tumours; Recovery; Chemotherapy; Cisplatin; Intensification; RANDOMIZED-TRIAL; CHEMOTHERAPY; CISPLATIN; SEMINOMA; DIAGNOSIS;

D O I：

10.1007/s10269-014-2383-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Testicular tumours are the most common form of cancer in young men. Since the 1970s, metastatic germ cell tumours have become the curable cancer paradigm through the use of cisplatin-based chemotherapy and surgical removal of the residual mass. The prognosis for patients is defined using the International IGCCCG classification, which enables the appropriate amount of chemotherapy therapy to be administered in order to achieve recovery. In the most serious forms, early adaptation of the chemotherapy regimen based on the decreasing levels of serum markers has been shown to be effective. Despite these treatments, approximately 20% of patients relapse and require a second line treatment, either at a standard dose or at an intensified level with a stem cell transplant. Follow-up of patients in complete remission is important, not only for the early detection of any relapses, but also to screen for testicular cancer in the other side, associated with the potential desire to father a child, and favours the best possible social rehabilitation of the patient.

引用

页码：161 / 165

页数：5

共 18 条

[1] 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial [J].

Bachner, M. ;

Loriot, Y. ;

Gross-Goupil, M. ;

Zucali, P. A. ;

Horwich, A. ;

Germa-Lluch, J. -R. ;

Kollmannsberger, C. ;

Stoiber, F. ;

Flechon, A. ;

Oechsle, K. ;

Gillessen, S. ;

Oldenburg, J. ;

Cohn-Cedermark, G. ;

Daugaard, G. ;

Morelli, F. ;

Sella, A. ;

Harland, S. ;

Kerst, M. ;

Gampe, J. ;

Dittrich, C. ;

Fizazi, K. ;

De Santis, M. .

ANNALS OF ONCOLOGY, 2012, 23 (01) :59-64

[2] Nonseminomatous germ cell tumors: Assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis [J].

Besse, Benjamin ;

Grunenwald, Dominique ;

Flechon, Aude ;

Caty, Armelle ;

Chevreau, Christine ;

Culine, Stephane ;

Theodore, Christine ;

Fizazi, Karim .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (02) :448-452

[3] Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer [J].

Beyer, J. ;

Albers, P. ;

Altena, R. ;

Aparicio, J. ;

Bokemeyer, C. ;

Busch, J. ;

Cathomas, R. ;

Cavallin-Stahl, E. ;

Clarke, N. W. ;

Classen, J. ;

Cohn-Cedermark, G. ;

Dahl, A. A. ;

Daugaard, G. ;

De Giorgi, U. ;

De Santis, M. ;

De Wit, M. ;

De Wit, R. ;

Dieckmann, K. P. ;

Fenner, M. ;

Fizazi, K. ;

Flechon, A. ;

Fossa, S. D. ;

Germa Lluch, J. R. ;

Gietema, J. A. ;

Gillessen, S. ;

Giwercman, A. ;

Hartmann, J. T. ;

Heidenreich, A. ;

Hentrich, M. ;

Honecker, F. ;

Horwich, A. ;

Huddart, R. A. ;

Kliesch, S. ;

Kollmannsberger, C. ;

Krege, S. ;

Laguna, M. P. ;

Looijenga, L. H. J. ;

Lorch, A. ;

Lotz, J. P. ;

Mayer, F. ;

Necchi, A. ;

Nicolai, N. ;

Nuver, J. ;

Oechsle, K. ;

Oldenburg, J. ;

Oosterhuis, J. W. ;

Powles, T. ;

Rajpert-De Meyts, E. ;

Rick, O. ;

Rosti, G. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :878-888

[4] Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy [J].

Beyer, Joerg ;

Lorch, Anja ;

Beyer, Joerg ;

Bascoul-Mollevi, C. ;

Kramar, A. ;

Einhorn, Lawrence H. ;

Necchi, A. ;

Massard, C. ;

De Giorgi, U. ;

Flechon, A. ;

Margolin, Kim A. ;

Lotz, Jean-Pierre ;

Lluch, Jose Ramon Germa ;

Powles, Thomas ;

Kollmannsberger, Christian K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4906-4911

[5] Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].

Collette, L ;

Sylvester, RJ ;

Stenning, SP ;

Fossa, SD ;

Mead, GM ;

de Wit, R ;

de Mulder, PHM ;

Neymark, N ;

Lallemand, E ;

Kaye, SB .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846

[6] Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors:: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T9313P) [J].

Culine, S. ;

Kerbrat, P. ;

Kramar, A. ;

Theodore, C. ;

ChevreauU, C. ;

Geoffrois, L. ;

Bui, N. B. ;

Peny, J. ;

Caty, A. ;

Delva, R. ;

Biron, P. ;

Fizazi, K. ;

Bouzy, J. ;

Droz, J. P. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :917-924

[7] Treatment of testicular cancer [J].

Droz, Jean-Pierre ;

Boyle, Helen ;

Culine, Stephane ;

Fizazi, Karim ;

Flechon, Aude ;

Massard, Christophe .

BULLETIN DU CANCER, 2013, 100 (12) :1319-1332

[8] Chemotherapy in patients with teratoma with malignant transformation [J].

El Mesbahi, Omar ;

Terrier-Lacombe, Marie-Josee ;

Rebischung, Christine ;

Theodore, Christine ;

Vanel, Daniel ;

Fizazi, Karim .

EUROPEAN UROLOGY, 2007, 51 (05) :1306-1312

[9] Primary mediastinal nonseminomatous germ cell tumors:: Results of modern therapy including cisplatin-based chemotherapy [J].

Fizazi, K ;

Culine, S ;

Droz, JP ;

Kramar, A ;

Théodore, C ;

Ruffié, P ;

Le Chevalier, T .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :725-732

[10] Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors [J].

Fizazi, K ;

Culine, S ;

Kramar, A ;

Amato, RJ ;

Bouzy, J ;

Chen, I ;

Droz, JP ;

Logothetis, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3868-3876

← 1 2 →